Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HALO 
Halozyme Therapeutics Inc (HALO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: HALO (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 42.56% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.89B USD | Price to earnings Ratio 18.61 | 1Y Target Price 67.75 |
Price to earnings Ratio 18.61 | 1Y Target Price 67.75 | ||
Volume (30-day avg) 1493456 | Beta 1.32 | 52 Weeks Range 37.73 - 66.00 | Updated Date 03/30/2025 |
52 Weeks Range 37.73 - 66.00 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 43.74% | Operating Margin (TTM) 58.89% |
Management Effectiveness
Return on Assets (TTM) 18.16% | Return on Equity (TTM) 198.42% |
Valuation
Trailing PE 18.61 | Forward PE 13.79 | Enterprise Value 8796090510 | Price to Sales(TTM) 7.77 |
Enterprise Value 8796090510 | Price to Sales(TTM) 7.77 | ||
Enterprise Value to Revenue 8.66 | Enterprise Value to EBITDA 13.4 | Shares Outstanding 123533000 | Shares Floating 121795854 |
Shares Outstanding 123533000 | Shares Floating 121795854 | ||
Percent Insiders 1.16 | Percent Institutions 102.38 |
Analyst Ratings
Rating 3.89 | Target Price 65.38 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Halozyme Therapeutics Inc
Company Overview
History and Background
Halozyme Therapeutics, Inc. was founded in 1998. Initially focused on recombinant human hyaluronidase (rHuPH20) technology, it evolved from drug delivery enhancement to oncology drug development. Key milestones include the development of ENHANZE drug delivery technology and strategic acquisitions.
Core Business Areas
- ENHANZE Technology: Licenses its ENHANZE drug delivery technology to pharmaceutical and biotechnology companies, enabling subcutaneous delivery of injectable biologics that are typically administered intravenously.
- Royalty Revenue: Generates revenue through royalties on sales of partnered products utilizing the ENHANZE technology.
Leadership and Structure
Halozyme is led by Helen Torley (CEO). The organizational structure includes departments for research and development, commercial operations, finance, and legal. It operates with a board of directors overseeing strategy and governance.
Top Products and Market Share
Key Offerings
- ENHANZE Technology Platform: This patented platform enables subcutaneous delivery of drugs that would otherwise require IV administration. Revenue is generated via royalty on sales of drugs using ENHANZE. Competitors include companies developing alternative delivery systems and direct IV infusions. While Halozyme doesn't report market share directly, ENHANZE is used in several approved and marketed drugs including Darzalex Faspro by Johnson & Johnson and Phesgo by Roche, both significant oncology drugs.
Market Dynamics
Industry Overview
The pharmaceutical drug delivery market is driven by the need for improved patient convenience, reduced healthcare costs, and enhanced drug efficacy. Subcutaneous drug delivery is gaining traction as a preferred alternative to intravenous administration.
Positioning
Halozyme holds a leading position in subcutaneous drug delivery through its ENHANZE technology. Its competitive advantage lies in its patented platform and established partnerships with major pharmaceutical companies.
Total Addressable Market (TAM)
The global drug delivery market is estimated in the hundreds of billions. Halozyme is positioned to capture a substantial portion of the subcutaneous drug delivery segment, which is expected to grow significantly. The current total addressable market for ENHANZE is related to the drugs it enhances; it is well-positioned with drugs like Darzalex FASPRO.
Upturn SWOT Analysis
Strengths
- Proprietary ENHANZE technology
- Established partnerships with major pharmaceutical companies
- Recurring royalty revenue stream
- Strong IP protection
- Experienced leadership team
Weaknesses
- Reliance on partners' success for royalty revenue
- Potential for generic competition to partnered drugs
- Susceptible to clinical trial failures of partnered drugs
Opportunities
- Expanding ENHANZE technology to new therapeutic areas
- Developing new drug delivery technologies
- Partnering with additional pharmaceutical companies
- Geographic expansion
Threats
- Competition from alternative drug delivery technologies
- Patent challenges to ENHANZE technology
- Regulatory changes
- Economic downturn impacting pharmaceutical spending
Competitors and Market Share
Key Competitors
- ARGN
- BMY
- JNJ
- RHHBY
Competitive Landscape
Halozyme's competitive advantage lies in its proven ENHANZE technology and its partnerships with leading pharmaceutical companies. Disadvantages include reliance on these partners and the potential for competing drug delivery technologies to emerge.
Major Acquisitions
Antares Pharma
- Year: 2022
- Acquisition Price (USD millions): 960
- Strategic Rationale: Acquisition of Antares Pharma expands Halozyme's portfolio and enhances its subcutaneous drug delivery capabilities.
Growth Trajectory and Initiatives
Historical Growth: Halozyme's growth has been driven by the increasing adoption of its ENHANZE technology and the success of its partnered products. Royalty revenue has steadily increased over the past years.
Future Projections: Analysts project continued growth for Halozyme, driven by new partnerships and expanded use of ENHANZE in existing products. These projections depend heavily on the successful outcomes of partnered drugs.
Recent Initiatives: Recent initiatives include securing new partnerships for ENHANZE, expanding its oncology pipeline, and exploring new therapeutic applications for its technology.
Summary
Halozyme Therapeutics demonstrates strength through its ENHANZE technology and established pharmaceutical partnerships, generating steady royalty revenue. Its dependency on partner's success and potential for competitor's products can be a threat. Expansion to new therapeutic areas will enhance it's business and technology. It is in a good position to leverage its technological advancement. The company should look out for clinical trial failures of partnered drugs.
Similar Companies
- ARGN
- BMY
- JNJ
- RHHBY
Sources and Disclaimers
Data Sources:
- Halozyme Therapeutics Inc. Investor Relations
- Company Filings (SEC)
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Halozyme Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-03-16 | President, CEO & Director Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 350 | Website https://halozyme.com |
Full time employees 350 | Website https://halozyme.com | ||
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.